Results of the CHAMPION (cardioMEMS heart sensor allows monitoring of pressure to improve outcomes in NYHA Class III Patients) clinical trial were recently published online in The Lancet.
The system incorporates a compact wireless sensor that provides pulmonary artery pressures in heart failure patients, greatly reducing the chances of re-hospitalization.
The Trial complied with security and secondary efficacy endpoints. Patients were chosen randomly from various health centers across the USA. Dr. William Abraham at the Ohio State University Medical Center together with Dr Philip Adamson from the Oklahoma Hearth Hospital jointly conducted the trials that were held to primarily determine the efficiency of the system introduced by CardioMEMS'. Currently, almost 30% of heart patients belong to the Class III category.
The sensor was implanted permanently in the pulmonary artery of all patients who underwent the trials. This was made possible by a catheter procedure. Heart pressures were monitored on a daily basis and the results relayed to the company’s patient database and relayed to the attending physician. The system reduces hospitalization, thus reducing costs while enhancing the quality of patient care.